TO THE EDITOR
Resistance to chemotherapy is a major problem in the treatment of acute myeloid leukemia (AML). As cytosine-arabinoside (Ara-C) is an important agent in the treatment of AML it is conceivable that leukemic blasts become resistant to Ara-C during the development to relapse/resistant disease. Ara-C is a cytotoxic nucleoside analogue which is phosphorylated intracellularly into its active form Ara-CTP, by the action of three enzymes: deoxycytidine kinase (dCK), deoxycytidine monophosphate (dCMP) kinase and nucleoside diphosphate (NDP) kinase. Ara-CTP inhibits DNA polymerase, and acts by competing with its physiological counterpart, the natural substrate dCTP, for incorporation into nucleic acids. Although several resistance mechanisms are involved in Ara-C metabolism, deoxycytidine kinase (dCK) is of particular interest because it is the rate-limiting enzyme in the phosphorylation process from Ara-C to Ara-CTP. Structural analysis of the dCK gene has revealed mutations which are associated with dCK deficiency and Ara-C resistance in vitro and in vivo.
Flasshove et al 1 found two silent point mutations (codon 86 and 42), and five mutations resulting in amino acid changes (codon 20, 93, 99, 98, 154) in the dCK cDNA in seven out of 16 adult patients with relapsed and refractory AML. One of them, a point mutation in codon 99 (TAT → TGT) leading to an amino acid substitution from tyrosine to cysteine, was associated with absent dCK activity, whereas the enzyme activity was normal in patients with a point mutation in codon 98 and 20.
We searched for mutations in the dCK gene in a unique set of paired purified bone marrow samples obtained from 30 AML patients at diagnosis and at relapse and/or refractory disease and from one CML patient at first and second blast crisis (10 children, 21 adults). All patients had been treated with chemotherapy according to national protocols including anthracyclines and Ara-C.
Initially, we used the procedure as described by Flasshove et al.
1
Briefly, total RNA was isolated and converted to cDNA in a reverse transcriptase reaction. The dCK cDNA was amplified by polymerase chain reaction (PCR) using Taq polymerase and two primers, flanking the dCK coding sequence as described. The single PCR product of 884 base pairs, that could be detected in all samples, was cloned into pCR II (TA cloning kit; Invitrogen, Carlsbad, CA, USA). Both strands of at least three clones from 21 diagnostic samples and 25 samples of relapsed and/or refractory AML patients were completely sequenced. Thirty-three different point mutations were found (12 silent and 21 giving rise to amino acid substitutions) in the diagnostic samples, and 61 mutations were found (15 silent and 46 giving rise to amino acid substitutions) in the relapse samples. Some dCK inserts contained no mutations at all whereas others, derived from the same patient sample, displayed multiple mutations. Mutations found in diagnostic samples were not detected in relapse samples of the same patient, nor was the reverse observed. Both the large number of silent mutations that cannot give rise to altered dCK enzymic activity and the abundant number of randomly found mutations suggest that these were experimental artifacts. Therefore, to adjust our procedure, we used another thermostable DNA polymerase that, in contrast to Taq DNA polymerase, possesses 3Ј to 5Ј exonuclease proofreading activity enabling the polymerase to correct nucleotide incorporation errors. Secondly, we used a direct method to sequence the amplified PCR product. We attempted to use high-fidelity Pfu DNA polymerase but were unable to reliably amplify dCK cDNA. These problems were solved using the Expand High Fidelity PCR System (Roche, Mannheim, Germany), which uses a mixture of Taq and Pwo DNA polymerase which displays proofreading activity. The modified procedure, ie the direct sequencing of dCK cDNAs obtained by RT-PCR from 31 paired samples of patients, revealed no mutations in any of the 62 samples. None of the previously described mutations by Flasshove, involving codons 20, 93, 98, 99 and 154 were found, nor the silent mutations in codon 42 and 86.
1 In addition, we did not observe new mutations at the time of relapse or at diagnosis, or other mutations that have been described in cell lines. 2 The abundant number of mutations detected if the method by Flasshove et al is used, is most likely due to the relatively low fidelity of the Taq polymerase. Our results raise the question whether the seven mutations found by Flasshove in 16 AML patients were true mutations, as the presence of the mutations was not confirmed at the genomic level and only one of them was translated to a reduced dCK activity. To our knowledge, the present study reports the largest group of AML patients that has been investigated for dCK mutations, and the first group with a respectable number of sequential samples. The results of this study show, that dCK mutations are not frequently observed and that they have no clinical relevance in the occurrence of Ara-C resistance in AML patients.
Several other studies showed that a decreased dCK activity was not associated with mutations in the dCK gene. A study performed by Kobayashi et al 3 did not reveal mutations in the cDNA coding region of the dCK gene in the human Ara-C resistant cell line KY-RA. Stammler et al 4 showed that pediatric ALL patients at diagnosis were more susceptible to relapse if dCK expression was low, but they did not find any mutations in the dCK cDNA. Kakihara et al 5 reported a great variability of dCK gene expression in a limited number of ALL and AML patients at diagnosis. In the two patients who were investigated both at diagnosis and at relapse, a lower dCK mRNA expression at relapse as compared to diagnosis state was observed. No dCK point mutations were found in this study. Martincic et al 6 observed Ara-C resistance in vitro in bone marrow samples of 5/7 AML patients of whom four had decreased levels of dCK mRNA levels. Using dideoxy fingerprinting (ddf) of the full-length dCK coding sequence, they did not find any mutations.
As dCK is the rate-limiting step in the phosphorylation cascade of Ara-C, it remains an interesting question which biological mechanism is responsible for the reduced or absent dCK activity if no mutations were found in the dCK cDNA. Recently, Veuger et al 7 described AML patients in whom the resistant phenotype was not associated with dCK mutations, but with the expression of alternative splice variants in addition to the wild-type dCK. The alternatively spliced transcripts, in which one or more exons were deleted, were shown to code for enzymic inactive proteins in vitro. 8 In our study, we did not amplify aberantly spliced dCK variants. There is some evidence that hypermethylation of the cgcg boxes of the promoter region of the dCK gene may cause dCK downregulation in cells. However, in a study of eight Ara-C-resistant AML patients the dCK 5Ј CpG islands were largely unmethylated. 6 As dCK activity was not measured in these patients, the direct effect of a variegated methylated promoter region of the dCK gene is not yet known. Therefore, it should be concluded that the role of dCK is still unknown, and that other steps in Ara-C metabolism such as reduced deoxycytidine deaminase (cDD) activity, enhanced DNA repair mechanisms or an impaired apoptosis pathway may also have clinical and biological importance. Based on our observations in a large panel of paired clinical samples and reports from the literature we conclude therefore, that mutations in the dCK gene are scarce and have no significant importance in the development of Ara-C resistance and refractory disease in AML.
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Spontaneous remission from RAEB in a child

TO THE EDITOR
The term myelodysplastic syndromes (MDS) includes a group of hematologic disorders characterized by cytopenia of various degrees, in combination with a hypercellular bone marrow showing dysplastic changes. Current knowledge in this field, as to pediatric cases, lags behind that of childhood acute leukemias as a consequence of many concurrent factors including lower incidence, uncertain classification, difficult diagnosis, variability of the clinical picture, some possibly associated conditions and the lack of consistent cytogenetic abnormalities specific to a single disorder.
1,2 Refractory anemia (RA), RA with excessive blasts (RAEB), RAEB in transformation (RAEB-T), RA with ringed sideroblasts (RARS), and chronic myelomonocytic leukemia (CMML, recently named JMML), 3 are the main categories of MDS as set out in the French-American-British (FAB) classification. 4 RAEB accounts for about one quarter of all MDS cases. The main features of RAEB are median age at presentation of 7 years, blast cells Ͻ5%, dysplasia and cytopenia of two or more cell lines in the peripheral blood, granulocytic or erythroid hyperplasia, dysplasia of myeloid, erythroid and/or megakaryocytic cell lines in the bone marrow.
1,2,4
Standard treatment of childhood RAEB remains controversial. Most patients progress to develop acute leukemia.
2 In such patients intensive chemotherapy has been less successful than in acute myeloid leukemia because of refractory disease, as well as a high rate of toxic death, related to more prolonged cytopenia.
2 Therefore, myeloablative therapy supported by a bone marrow transplant may be necessary. 5, 6 Nevertheless, sporadic reports of spontaneous remission may challenge this approach. We report a long lasting spontaneous remission from RAEB in an infant.
RA, a female, born in August 1995, was first admitted to hospital at the age of 7 months because of persistent low-grade fever and weight loss (350 g over 2 weeks). She weighed 6.450 kg (between the 5th and 10th centiles for her age) and was 67 cm long (25-50th centiles). Small cervical lymph nodes were palpable. All tests were negative except for an abnormal white blood cell (WBC) count of 20 500/mm 3 and a urine culture which grew 5 000 000 CFU/ml of E. coli). She was successfully treated with antibiotics and discharged
